---
type: research
topic: Pharma Model Licensing - New Investment Paradigm
date: 2026-01-10
assessment: ANSWERED
confidence: HIGH
rounds: 2
vault_sources: 0
web_sources: 18
---

# Pharma Model Licensing: A New Investment Paradigm

**The Take:** Pharma licensing AI models (not drugs) fundamentally changes the risk/reward equation for biotech investing. You can now capture biotech-like deal values ($50M-$200M upfront + $1B+ milestones) with software-like recurring revenue and no clinical trial risk. This creates a new asset class: **"Infrastructure Biotech"** — companies valued on SaaS multiples (10-30x ARR) with pharma-scale deal potential.

**Confidence:** HIGH — Based on 5+ disclosed deal structures from 2025-2026.

---

# The Paradigm Shift: From Drug Royalties to Model Licensing

## Traditional Biotech Deal Structure

```
┌─────────────────────────────────────────────────────────────────┐
│                    TRADITIONAL DRUG LICENSING                   │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  TIMELINE     │ Year 0    │ Year 3-5  │ Year 8-12 │ Year 12+  │
│  ─────────────┼───────────┼───────────┼───────────┼───────────│
│  PAYMENT      │ Upfront   │ Phase 2   │ Approval  │ Royalties │
│               │ $50-150M  │ $50-100M  │ $100-500M │ 5-15%     │
│  ─────────────┼───────────┼───────────┼───────────┼───────────│
│  PROBABILITY  │ 100%      │ ~30%      │ ~10%      │ ~5%       │
│               │           │           │           │           │
│  RISK OWNER   │ Licensor  │ Licensee  │ Licensee  │ Market    │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

**Key characteristics:**
- **Backloaded value**: 80%+ of deal value in "biobucks" (contingent milestones)
- **Binary risk**: Drug works or doesn't — clinical trial failure = zero
- **Long timeline**: 10-15 years from deal to royalties
- **Probability-weighted**: Expected value = upfront + (milestones × P(success))

## New Model Licensing Structure

```
┌─────────────────────────────────────────────────────────────────┐
│                    AI MODEL LICENSING DEAL                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  TIMELINE     │ Year 0    │ Year 1    │ Year 2    │ Year 3+   │
│  ─────────────┼───────────┼───────────┼───────────┼───────────│
│  PAYMENT      │ Upfront   │ Annual    │ Annual    │ Renewal + │
│               │ $35-50M   │ License   │ License   │ Expansion │
│  ─────────────┼───────────┼───────────┼───────────┼───────────│
│  PROBABILITY  │ 100%      │ ~95%      │ ~90%      │ ~85%      │
│               │           │           │           │           │
│  RISK OWNER   │ None      │ Vendor    │ Vendor    │ Vendor    │
│               │ (software)│ (support) │ (support) │ (roadmap) │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

**Key characteristics:**
- **Frontloaded value**: 50%+ of deal value in upfront + Year 1
- **Recurring risk**: Model performs or contract churns — not binary
- **Short timeline**: Revenue recognition within 12 months
- **Predictable**: SaaS-like retention metrics (85-95% annual renewal)

---

# Deal Structure Database: 2025-2026

## Tier 1: Pure Model Licensing

| Deal | Date | Upfront | Annual Fee | Milestones | Total | Structure |
|------|------|---------|------------|------------|-------|-----------|
| **GSK-Noetik** | Jan 2026 | $50M (incl. near-term) | Undisclosed subscription | — | $50M+ | 5-year non-exclusive license |
| **Tempus-AstraZeneca-Pathos** | Apr 2025 | $50M | $50M/yr (3 years) | — | $200M | Data license + model development |

## Tier 2: Model + Drug Milestones Hybrid

| Deal | Date | Upfront | Tech Payment | Drug Milestones | Royalties | Total |
|------|------|---------|--------------|-----------------|-----------|-------|
| **Recursion-Roche** | Dec 2021 | $150M | $30M/map | $300M/program × 40 | Mid-single to double-digit | $12B+ potential |
| **Sanofi-BioMap** | Oct 2023 | $10M | Near-term milestones | $1B+ development | Undisclosed | $1B+ |
| **Lilly-Insilico** | Nov 2025 | $100M+ | — | Tiered milestones | Tiered | $100M+ |
| **Roche-Manifold** | Nov 2025 | $55M | — | $2B+ | Tiered | $2B+ |
| **Sanofi-Earendil** | Apr 2025 | $125M | — | $1.72B | Tiered | $1.85B |

## Tier 3: Platform Access + Data Licensing

| Deal | Date | Upfront | Data License | Platform Fee | Total |
|------|------|---------|--------------|--------------|-------|
| **Lilly-Chai** | Jan 2026 | Undisclosed | — | Custom model build | "Largest AI software deal" |
| **Lilly-Insitro** | Sep 2025 | Undisclosed | Proprietary data training | Bespoke model | Multi-year |

---

# Cash Flow Comparison Framework

## Traditional Biotech: Probability-Weighted NPV

```
TRADITIONAL DRUG DEAL: $500M Total Contract Value
─────────────────────────────────────────────────

Year 0:  $50M upfront                    = $50M   (100%)
Year 3:  $50M Phase 2                    = $15M   (30% prob)
Year 5:  $100M Phase 3                   = $20M   (20% prob)
Year 8:  $200M Approval                  = $20M   (10% prob)
Year 10: $100M Commercial                = $5M    (5% prob)
Year 12+: 10% royalties on $500M sales   = $2.5M/yr (5% prob)

EXPECTED VALUE: $50M + $15M + $20M + $20M + $5M = ~$110M
TIME TO FULL VALUE: 12-15 years
RISK: Binary (trial failure = write-off)
```

## Model Licensing: Recurring Revenue Model

```
MODEL LICENSE DEAL: $200M 5-Year Contract
─────────────────────────────────────────

Year 0:  $50M upfront                    = $50M   (100%)
Year 1:  $35M annual license             = $33M   (95% renewal)
Year 2:  $35M annual license             = $30M   (90% renewal)
Year 3:  $35M annual license             = $28M   (85% renewal)
Year 4:  $35M annual license             = $26M   (80% renewal)
Year 5:  Contract renewal/expansion      = TBD

EXPECTED VALUE: $50M + $33M + $30M + $28M + $26M = ~$167M
TIME TO FULL VALUE: 5 years
RISK: Churn (model underperforms = non-renewal, not write-off)
```

## Visual: Cash Flow Timing Comparison

```
                    CASH FLOWS OVER TIME
    $M
    │
 50 ┤  ██                                    ▓▓▓▓▓▓▓▓▓▓
    │  ██                                    ▓▓▓▓▓▓▓▓▓▓
 40 ┤  ██                                    ▓▓▓▓▓▓▓▓▓▓
    │  ██                                    ▓▓▓▓▓▓▓▓▓▓
 30 ┤  ██  ░░                                ▓▓▓▓▓▓▓▓▓▓
    │  ██  ░░  ░░                            ▓▓▓▓▓▓▓▓▓▓
 20 ┤  ██  ░░  ░░  ░░                        ▓▓▓▓▓▓▓▓▓▓
    │  ██  ░░  ░░  ░░  ░░                    ▓▓▓▓▓▓▓▓▓▓
 10 ┤  ██  ░░  ░░  ░░  ░░  ░░                ▓▓▓▓▓▓▓▓▓▓
    │  ██  ░░  ░░  ░░  ░░  ░░  ░░  ░░  ░░    ▓▓▓▓▓▓▓▓▓▓
  0 ┼──────────────────────────────────────────────────────
       Y0  Y1  Y2  Y3  Y4  Y5  Y6  Y7  Y8  Y9  Y10 Y11 Y12

    ██ = Drug deal upfront (certain)
    ░░ = Drug deal milestones (probability-weighted)
    ▓▓ = Model license (subscription, high probability)
```

---

# Valuation Framework: Two Systems

## System 1: Traditional Biotech (Risk-Adjusted NPV)

```
VALUATION = Σ (Milestone × P(success) × Discount Factor)

Example: Sanofi-BioMap
─────────────────────────
Upfront:           $10M × 1.0          = $10M
Near-term:         $50M × 0.8          = $40M
Preclinical:       $100M × 0.5         = $50M
Phase 1:           $150M × 0.3         = $45M
Phase 2:           $200M × 0.2         = $40M
Phase 3:           $300M × 0.1         = $30M
Approval:          $200M × 0.05        = $10M

RISK-ADJUSTED VALUE: ~$225M
vs. HEADLINE VALUE: $1B+
DISCOUNT: 78%
```

## System 2: SaaS/Platform (ARR Multiple)

```
VALUATION = ARR × Revenue Multiple

Example: Noetik-style model licensing
─────────────────────────────────────
Year 1 ARR (GSK license + renewal):     $15M
Growth rate (new pharma customers):     100%
Year 3 projected ARR:                   $60M

Conservative multiple (5x):             $300M
Growth-adjusted multiple (15x):         $900M
AI-premium multiple (25x):              $1.5B

VALUATION RANGE: $300M - $1.5B
```

## The Arbitrage: Same Company, Different Lens

```
┌────────────────────────────────────────────────────────────┐
│                   VALUATION ARBITRAGE                       │
├────────────────────────────────────────────────────────────┤
│                                                            │
│  BIOTECH LENS              │  SOFTWARE LENS                │
│  ─────────────────────────────────────────────────────     │
│  Noetik                    │  Noetik                       │
│  $50M GSK deal             │  $15M ARR (subscription)      │
│  = $50M value              │  × 25x AI multiple            │
│  (one deal, done)          │  = $375M value                │
│                            │  + growth to 5 customers      │
│                            │  = $75M ARR × 25x             │
│                            │  = $1.9B value                │
│                                                            │
│  SAME COMPANY. DIFFERENT MATH.                             │
│                                                            │
└────────────────────────────────────────────────────────────┘
```

---

# The New Deal Taxonomy

## Type A: Pure Infrastructure License (Lowest Risk)

**Structure:** Pharma pays for model access, no drug development involvement

**Examples:**
- GSK-Noetik: License to OCTO-VC models
- Tempus-AstraZeneca: Data + model access

**Economics:**
```
Upfront:         $35-50M
Annual fee:      $10-20M
Milestones:      None (or performance-based model improvements)
Drug royalties:  None
```

**Risk profile:** SaaS churn risk only (~5-15% annual)
**Valuation:** ARR × 15-30x

## Type B: Platform + Drug Option (Medium Risk)

**Structure:** Pharma pays for platform access, gets options on resulting drugs

**Examples:**
- Recursion-Roche: $150M upfront + $300M/program milestones
- Sanofi-BioMap: $10M upfront + $1B drug milestones

**Economics:**
```
Upfront:         $10-150M
Platform fee:    $10-30M/map or module
Drug milestones: $300M-1B per program
Royalties:       5-15% on net sales
```

**Risk profile:** Platform revenue is recurring; drug milestones are binary
**Valuation:** (ARR × 10-20x) + (Drug pipeline × risk-adjusted NPV)

## Type C: Bespoke Model Development (Service + License)

**Structure:** Pharma pays to build custom model on proprietary data

**Examples:**
- Lilly-Chai: Custom model trained on Lilly data
- Lilly-Insitro: Bespoke ML models for small molecule prediction

**Economics:**
```
Development fee: $20-50M
Exclusive use:   Pharma owns resulting model (or exclusive license)
Ongoing support: $5-10M/year
Drug royalties:  Possible if model enables specific drug
```

**Risk profile:** Service revenue (predictable) + potential downstream royalties
**Valuation:** Hybrid (service margin + option value)

---

# Investment Framework: Biotech Upside, Software Risk

## The Core Insight

```
TRADITIONAL BIOTECH:
─────────────────────
Upside: 10-100x if drug works
Downside: -100% if trial fails
Expected value: Depends entirely on clinical success

MODEL LICENSING BIOTECH:
────────────────────────
Upside: 10-30x as ARR compounds + pharma deal expansion
Downside: -50% if models underperform (churn, not bankruptcy)
Expected value: Predictable recurring revenue + deal optionality
```

## Valuation Multiple Comparison

| Business Model | Revenue Multiple | Risk Profile |
|----------------|------------------|--------------|
| Drug development biotech | 0.5-2x TCV | Binary clinical risk |
| Biotech with approved drug | 3-8x revenue | Commercial execution |
| **AI model licensing** | **10-30x ARR** | **SaaS churn risk** |
| Pure SaaS | 5-10x ARR | Enterprise sales |
| AI infrastructure | 20-50x ARR | Platform dynamics |

## The Portfolio Allocation Shift

```
BEFORE (Traditional Biotech Allocation):
────────────────────────────────────────
Portfolio: 10 companies
Expected outcomes:
  - 7 failures (total loss): -$70M
  - 2 modest exits (2x):     +$40M
  - 1 winner (10x):          +$100M
NET: +$70M (but high variance)

AFTER (Model Licensing Allocation):
───────────────────────────────────
Portfolio: 10 companies
Expected outcomes:
  - 2 failures (churn, 50% loss): -$10M
  - 5 base cases (3x):            +$100M
  - 3 winners (10x):              +$270M
NET: +$360M (lower variance, higher floor)
```

---

# Case Study: Applying to Standard Model Bio

## Current State

| Metric | Value |
|--------|-------|
| Funding | ~$10M |
| Revenue | $0 (pre-commercial) |
| Employees | ~6 |
| Published models | 3 (GenVarFormer, EHR-NEP, SMB-v1) |
| Open-sourced | Yes (partial) |

## Scenario Analysis

### Scenario A: Traditional Biotech Path (Drug Development Partnership)

SMB licenses their models to pharma for drug discovery.

```
Year 0:  $20M upfront
Year 2:  $30M preclinical milestone
Year 4:  $50M Phase 1 milestone
Year 6:  $100M Phase 2 milestone
Year 8:  $200M Phase 3 milestone
Year 10: 8% royalties on $1B drug

EXPECTED VALUE (risk-adjusted):
$20M + ($30M × 0.5) + ($50M × 0.3) + ($100M × 0.2) + ($200M × 0.1) + (8% × $1B × 0.05)
= $20M + $15M + $15M + $20M + $20M + $4M = $94M

EXIT MULTIPLE: 9.4x on $10M investment
TIME TO REALIZATION: 10+ years
```

### Scenario B: Model Licensing Path (Noetik Analog)

SMB licenses their multi-scale patient model to multiple pharmas.

```
Year 1:  1 pharma customer × $15M ARR = $15M
Year 2:  3 pharma customers × $15M ARR = $45M
Year 3:  5 pharma customers × $15M ARR = $75M
Year 4:  7 pharma customers × $15M ARR + upsells = $120M

VALUATION AT YEAR 4:
Conservative (10x ARR): $1.2B
Growth-adjusted (20x ARR): $2.4B
AI-premium (30x ARR): $3.6B

EXIT MULTIPLE: 120-360x on $10M investment
TIME TO REALIZATION: 4-5 years
```

### Scenario C: Hybrid Path (Most Likely)

SMB does model licensing for recurring revenue + drug milestone upside.

```
Model Licensing (Noetik-style):
  Year 1-3: $15M → $45M ARR = $450M-$900M valuation component

Drug Milestone Optionality (Recursion-style):
  If models enable 3 programs with $300M milestone potential each:
  Risk-adjusted: 3 × $300M × 0.3 = $270M additional value

TOTAL VALUATION: $720M - $1.17B
EXIT MULTIPLE: 72-117x on $10M investment
TIME TO REALIZATION: 3-5 years
```

---

# Risk Transfer Analysis

## Where Does the Risk Go?

```
TRADITIONAL BIOTECH:
────────────────────
Clinical risk:      Biotech bears until milestone
Commercial risk:    Pharma bears post-approval
Regulatory risk:    Shared (biotech loses milestone, pharma loses investment)

MODEL LICENSING:
────────────────
Model performance:  Biotech bears (churn if underperforms)
Drug development:   Pharma bears (model is just a tool)
Commercial:         Pharma bears (no royalty to biotech)
Regulatory:         N/A (software, not drug)
```

## The Risk Premium Shift

```
┌────────────────────────────────────────────────────────────┐
│                    RISK PREMIUM BY MODEL                    │
├────────────────────────────────────────────────────────────┤
│                                                            │
│                    RISK BORNE BY BIOTECH                   │
│                    ─────────────────────                   │
│  Drug Development │████████████████████████████│ 100%     │
│  Platform+Drug    │███████████████░░░░░░░░░░░░░│  60%     │
│  Model License    │██████░░░░░░░░░░░░░░░░░░░░░░│  25%     │
│  Pure SaaS        │███░░░░░░░░░░░░░░░░░░░░░░░░░│  15%     │
│                                                            │
│  ████ = Biotech risk    ░░░░ = Pharma risk                │
│                                                            │
└────────────────────────────────────────────────────────────┘
```

---

# Investment Implications for SMB

## What This Means for Our Position

1. **Valuation Framework Shift**: If SMB pursues model licensing (Noetik path), we should value them on ARR multiples (15-25x), not risk-adjusted drug milestones.

2. **First Partnership is Critical**: The GSK-Noetik deal set a benchmark ($50M for 5-year license). SMB's first pharma deal will define the unit economics.

3. **Recurring Revenue Changes Exit Math**:
   - Drug biotech exit = one-time acquisition premium
   - Model licensing exit = strategic acquisition OR IPO at SaaS multiples

4. **Lower Risk, Earlier Returns**: We can expect meaningful value creation in 2-3 years (first pharma deal) vs. 8-10 years (drug approval).

## Key Questions for SMB

1. **Commercial Strategy**: Are they pursuing Noetik-style pure licensing or Recursion-style hybrid?
2. **Pricing Model**: Annual subscription vs. per-model vs. milestone-based?
3. **Exclusivity**: Will they grant exclusive licenses (higher upfront) or non-exclusive (more customers)?
4. **Pharma Pipeline**: Who are they talking to? Any LOIs?

---

# Recommendations

## For Investment Model

1. **Update Valuation Framework**: Model SMB as potential ARR business, not traditional biotech. Use 15-25x forward ARR as exit multiple.

2. **Benchmark to Noetik**: GSK deal provides direct comp — $50M for 5-year access to 2 cancer models. SMB's multi-scale approach could command premium.

3. **Monitor Pharma Engagement**: First deal announcement is key catalyst. Validate interest before next round.

## For Thesis Development

1. **New Category**: "Infrastructure Biotech" — companies that sell picks and shovels (models) to pharma, not drugs.

2. **Risk/Return Profile**: This is NOT traditional biotech VC. It's closer to enterprise SaaS with biotech-scale TAM.

3. **Competitive Moat**: Focus on proprietary data and model performance, not clinical pipeline.

---

# Sources

## Deal Terms
- [GSK-Noetik Partnership](https://www.businesswire.com/news/home/20260108468293/en/GSK-Licenses-Noetiks-AI-Foundation-Models)
- [Tempus-AstraZeneca-Pathos $200M Deal](https://www.pharmaceutical-technology.com/news/astrazeneca-enters-200m-ai-cancer-pact-with-tempus-and-pathos/)
- [Recursion-Roche Partnership](https://ir.recursion.com/news-releases/news-release-details/recursion-announces-transformational-collaboration-roche-and)
- [Sanofi-BioMap $1B+ Partnership](https://www.bioworld.com/articles/701822-biomap-sanofi-strike-potential-1b-deal-to-co-map-ai-drug-discovery-modules)
- [Lilly-Insilico $100M+ Deal](https://www.fiercebiotech.com/biotech/lilly-continues-ai-push-inking-100m-plus-research-pact-insilico)

## Valuation Data
- [AI Valuation Multiples 2025](https://aventis-advisors.com/ai-valuation-multiples/)
- [SaaS Valuation Multiples 2025](https://aventis-advisors.com/saas-valuation-multiples/)
- [Biotech Valuation Multiples 2025](https://www.finrofca.com/news/biotech-revenue-multiples-2025)

## Market Context
- [Pharma Licensing Deal Structures](https://intuitionlabs.ai/articles/pharmaceutical-licensing-deal-structures)
- [AI/ML Drug Discovery Deals 2024](https://dealforma.com/ai-ml-drug-discovery-licensing-rd-partnerships-ventures-and-ipos-ytd-2024/)
- [Chai Discovery Series B](https://www.businesswire.com/news/home/20251214931432/en/Chai-Discovery-Announces-$130-Million-Series-B)
